📗 Cite This Artifact
PD Knowledge Gaps Ranked (Legacy Redirect)
PD Knowledge Gaps Ranked (Legacy Path)
This legacy page has been migrated to the canonical page at [Parkinson's Disease Knowledge Gaps](/gaps/parkinsons). However, this page is retained to provide a focused summary of the highest-priority research gaps in Parkinson's disease for quick reference.
Overview
Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease, affecting approximately 10 million people worldwide. Despite decades of research, fundamental questions about disease mechanisms, progression, and treatment remain unanswered. This page summarizes the critical knowledge gaps that, if addressed, could transform PD treatment and prevention.
The research landscape has evolved significantly with three major advances between 2024-2026:
The 2024-2026 Transformation in PD Research
...
PD Knowledge Gaps Ranked (Legacy Path)
This legacy page has been migrated to the canonical page at [Parkinson's Disease Knowledge Gaps](/gaps/parkinsons). However, this page is retained to provide a focused summary of the highest-priority research gaps in Parkinson's disease for quick reference.
Overview
Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease, affecting approximately 10 million people worldwide. Despite decades of research, fundamental questions about disease mechanisms, progression, and treatment remain unanswered. This page summarizes the critical knowledge gaps that, if addressed, could transform PD treatment and prevention.
The research landscape has evolved significantly with three major advances between 2024-2026:
The 2024-2026 Transformation in PD Research
The Parkinson's disease research landscape has entered a new era marked by three transformative advances that have fundamentally changed how we approach disease understanding, clinical trial design, and therapeutic development. These advances represent not merely incremental progress but qualitative shifts in our ability to diagnose, stratify, and treat PD.
GLP-1 Receptor Agonist Translation
The demonstration that lixisenatide, a GLP-1 receptor agonist approved for type 2 diabetes, can slow motor progression in early Parkinson's disease represents the first reproducible disease-modifying signal in PD clinical trials since the levodopa era. The phase 2 randomized controlled trial showed a statistically significant difference in Unified Parkinson's Disease Rating Scale (UPDRS) motor scores between treatment and placebo groups over 12 months[@pagano2024].
Mechanistic implications:
- GLP-1 receptors are expressed on dopaminergic neurons and microglia
- Anti-inflammatory and neurotrophic effects may contribute to neuroprotection
- Peripheral metabolic effects may influence brain function through multiple pathways
- Which patient subgroups respond best?
- What is the optimal duration of treatment?
- Can effects be maintained beyond 12 months?
LRRK2 Inhibitor Advancement
The LRRK2 G2019S mutation is the most common genetic cause of familial PD, and LRRK2 kinase hyperactivity is now recognized in sporadic PD. The development of brain-penetrant LRRK2 inhibitors that have reached clinical testing represents a major milestone[@jennings2023].
Key developments:
- BIIB122 (previously DNL151) completed Phase 1 and entered Phase 2
- Target engagement demonstrated in humans
- Safety profile supports continued development
- Demonstrating disease modification beyond target engagement
- Understanding which patients should receive treatment
- Managing potential peripheral toxicity
Alpha-Synuclein Seed Amplification
The alpha-synuclein seed amplification assay (SAA) has emerged as a transformative biomarker that can detect pathological alpha-synuclein in cerebrospinal fluid with high sensitivity and specificity[@simuni2023]. The assay enables:
- Biological definition of disease: SAA-positive individuals can be classified as having neuronal alpha-synuclein disease regardless of clinical presentation
- Prognostic stratification: SAA kinetic measures correlate with disease progression
- Trial enrichment: Identifying prodromal individuals for prevention trials
Top Priority Knowledge Gaps
Alpha-Synuclein Biology
The central role of alpha-synuclein in PD pathogenesis is well-established, but critical gaps remain:
Seed Kinetics and Progression:
- Do alpha-synuclein seed kinetics define biologically distinct progression trajectories?
- Can kinetic measures predict clinical progression rate?
- What drives inter-individual variation in seeding behavior?
- Which alpha-synuclein species and compartments are the true therapeutic targets?
- Are oligomers, fibrils, or strains the relevant toxic species?
- How do different aggregation states relate to cellular dysfunction?
- Understanding prion-like propagation from gut to brain
- Role of the vagus nerve in alpha-synuclein spread
- Contribution of peripheral sources to CNS pathology
Disease Modification
Translating biological insights into treatments remains challenging:
GLP-1 Responder Biology:
- Which early-PD subgroups truly benefit from GLP-1 pathway therapies?
- What biomarkers predict treatment response?
- What is the mechanism of neuroprotection?
- Can LRRK2 inhibition demonstrate disease modification beyond target engagement?
- Which patients should receive treatment (genetic vs sporadic)?
- What is the optimal timing of intervention?
- What is the optimal sequencing of disease-modifying regimens?
- Can multiple mechanisms be targeted simultaneously?
- What are synergistic combinations?
Selective Vulnerability
Why specific neurons degenerate early while others remain resilient:
- Substantia nigra vulnerability: What drives selective vulnerability of dopaminergic neurons in the substantia nigra?
- Cell-type resilience: Can we identify "resilient" cell programs for therapeutic induction?
- Mitochondrial failure: Which mitochondrial failure nodes are upstream vs secondary in PD?
Biomarkers and Trial Design
Improving clinical trial efficiency and patient selection:
- SAA kinetics for staging: How should SAA and imaging be combined for prodromal-trial enrichment?
- Digital endpoints: Can digital progression endpoints be validated and integrated?
- Multi-modal endpoints: How should trial endpoints integrate digital, fluid, imaging, and functional data?
Detailed Gap Analysis by Research Domain
Genetic Risk and Precision Medicine
The identification of over 90 genetic risk loci for PD has transformed our understanding of disease biology, but translating genetic insights into clinical care remains challenging.
Neuroinflammation and Glial Biology
Neuroinflammation is a consistent finding in PD brain tissue and may contribute to disease progression.
Protein Clearance Pathways
Impairment of autophagy and lysosomal function is a consistent finding in PD.
Scoring Framework
Knowledge gaps are evaluated on four dimensions (0-10 scale each):
| Dimension | Description |
|-----------|-------------|
| Impact if Solved | Potential to change treatment, prevention, or trial success |
| Tractability | Feasibility with current tools, cohorts, and assays |
| Under-exploration | Insufficient effort relative to importance |
| Data Availability | Availability of cohorts, biomarkers, models, and endpoints |
Current Highest-Ranked Gaps
2026 Research Priorities
Based on current knowledge gaps, the following research directions are recommended:
Recommended Clinical Trial Designs
| Trial Type | Population | Endpoints | Timeline |
|------------|-----------|-----------|----------|
| Prevention | SAA+ prodromal | SAA kinetics, clinical | 3-5 years |
| Disease modification | Early PD | Biomarker + clinical | 2-3 years |
| Combination | Established PD | Multi-modal | 1-2 years |
| Target validation | Genetically defined | Target engagement | 1-2 years |
Related Pages
- [Parkinson's Disease](/diseases/parkinsons-disease) - Main disease page
- [Parkinson's Disease Knowledge Gaps](/gaps/parkinsons) - Canonical gap analysis
- [Alpha-Synuclein](/proteins/alpha-synuclein) - Key protein
- [LRRK2](/genes/lrrk2) - Major genetic risk gene
- [Synuclein Pathway in Parkinson's Disease](/mechanisms/synuclein-pathway-parkinsons) - Core pathology mechanism
- [Parkinson's Disease Biomarkers](/biomarkers/parkinsons-disease-biomarkers) - Biomarker framework
External Resources
- [Michael J. Fox Foundation](https://www.michaeljfox.org/) - Parkinson's research funding
- [Parkinson's Foundation](https://www.parkinson.org/) - Patient resources and research
- [Parkinson's Progression Markers Initiative (PPMI)](https://www.ppmi-info.org/) - Longitudinal study dataset
See Also
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Alpha-Synuclein](/proteins/alpha-synuclein)
- [Parkinson's Disease Mechanisms](/mechanisms/parkinsons-disease-pathogenesis)
- [Research Gaps in Neurodegeneration](/gaps/neurodegeneration-overview)
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | mechanisms-pd-knowledge-gaps-ranked |
| kg_node_id | None |
| entity_type | mechanism |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-25aa56034737 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-pd-knowledge-gaps-ranked'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-mechanisms-pd-knowledge-gaps-ranked?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[PD Knowledge Gaps Ranked (Legacy Redirect)](http://scidex.ai/artifact/wiki-mechanisms-pd-knowledge-gaps-ranked)
http://scidex.ai/artifact/wiki-mechanisms-pd-knowledge-gaps-ranked